ICTCAR-028 by Innovative Cellular Therapeutics for Hematological Tumor: Likelihood of Approval

ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.

Jul 6, 2024 - 04:00

ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.

Read the original article

Tags:

Previous Article

CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of A...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: A new mom’s illness led to the first diagnosis of a rare condition after childbirth

STAT+: A new mom’s illness led to the first diagnosis o...

Aug 17, 2023

Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032

Atrial fibrillation market set to decline at a CAGR of ...

Jul 13, 2023

Listen: Live! From JPM 2024

Jan 12, 2024